AI-assisted scoring for gastric IM using EGGIM shows how well doctors trained

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this prospective randomized crossover trial, endoscopists view image-enhanced endoscopy videos of five stomach regions and score gastric intestinal metaplasia using the EGGIM system. Participants are stratified by experience and receive AI-assisted scoring in one phase and conventional scoring in a subsequent phase after a washout period. The study compares diagnostic performance metrics such as AUC, sensitivity, and specificity between AI-assisted and conventional scoring across phases to gauge training efficacy. It is conducted at Qilu Hospital of Shandong University in Jinan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Endoscopists who have performed ≥50 image-enhanced endoscopy (IEE) procedures per year and demonstrated competency in performing standardized IEE.

Exclusion Criteria:

Endoscopists who participated in data acquisition or were unblinded to patients' identifiable information and clinical data.

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Zhen Li
• Email: qilulizhen@sdu.edu.cn
• Phone: 86+18560086106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ursodeoxycholic acid for reversing gastric intestinal metaplasia

  This study will test whether taking ursodeoxycholic acid for six months can reverse gastric intestinal metaplasia in adults who do not have Helicobacter pylori infection.

  Recruiting at 6 sites Phase 4 Xijing Hospital of Digestive Diseases · Pingdingshan, Henan and 5 other locations · NCT06610760

• Weifuchun tablets versus folic acid to reverse gastric intestinal metaplasia

  This trial tries to see if taking Weifuchun tablets daily for six months can reverse gastric intestinal metaplasia in adults without Helicobacter pylori compared with daily folic acid.

  Recruiting at 9 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang and 8 other locations · NCT06610266

• Reversing stomach intestinal metaplasia using pyrvinium

  This trial will test whether a two-week course of the drug pyrvinium can reduce or reverse high-risk gastric intestinal metaplasia in adults at increased risk for stomach cancer.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT06590454

• Collecting health information to understand and prevent gastric cancer

  This study is trying to gather health information from people with early signs of gastric cancer, as well as healthy individuals and those already diagnosed, to better understand what might lead to this type of cancer.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06370143

• Monitoring patients with precancerous stomach lesions

  This study is trying to find out how to better monitor people with precancerous stomach lesions to see who is at risk of developing gastric cancer and when they should come back for check-ups.

  Recruiting University of Latvia · Riga · NCT03250091

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.